ReviewAdvances in urology2026
Unveiling the Potential of Fish Swim Bladder-Derived Biomaterials in Urological Care.
Review in Advances in urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fish swim bladder (FSB)-derived biomaterials have recently emerged as a promising marine-based extracellular matrix (ECM) platform with potential applications in urological tissue engineering and regenerative medicine. This narrative review synthesizes current evidence regarding the structural, biological, and functional properties of FSB and evaluates its potential role in urological reconstruction. This narrative review was conducted using the PubMed, Google Scholar, and ScienceDirect databases with predefined keywords related to FSB-derived biomaterials. Articles published from January 1, 2000, to December 31, 2025, were included. Eligible studies comprised original research, in vitro and in vivo experimental studies, and review articles. FSB is characterized by a high content of type I collagen, elastin, and glycosaminoglycans (GAGs), forming a well-organized, hydrated, and mechanically resilient matrix that closely resembles native mammalian ECM. These properties support cellular adhesion, proliferation, and tissue regeneration, while also modulating inflammatory responses during wound healing. Preclinical studies demonstrate that decellularized FSB scaffolds exhibit favorable mechanical properties, biocompatibility, and the ability to promote constructive tissue remodeling. In addition, hydrolyzed derivatives, such as gelatin and collagen peptides, have demonstrated antioxidant and regenerative properties. However, intrinsic antimicrobial activity remains limited, often requiring additional functionalization to achieve clinically relevant antibacterial effects. Safety considerations, including potential allergenicity, variability in raw materials, and the risk of microbial contamination, underscore the importance of standardized processing and rigorous sterilization protocols. Composition, thermal stability, and gelation behavior vary substantially across fish species, indicating that species selection is a critical determinant of scaffold performance. Despite encouraging findings in experimental models, clinical translation in urological applications remains limited. Further research focusing on organ-specific applications, long-term safety, and optimized scaffold design is essential. Overall, FSB-derived biomaterials represent a sustainable and versatile platform with significant potential to advance regenerative strategies in urological care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.